149 related articles for article (PubMed ID: 38180721)
21. Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial.
Lickliter J; Kanceva R; Vincent E; Schueler A; Harrison-Moench E; Yue CS; Stahl M; Ullmann M; Ghori V; Griffin P
Clin Ther; 2020 Aug; 42(8):1508-1518.e1. PubMed ID: 32660769
[TBL] [Abstract][Full Text] [Related]
22. Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease.
Pang Y; D'Cunha R; Mohammad AS; Wang Z; Duan R; Kalabic J; Anschutz T; Nudurupati S; Wallace K; Jaeschke M; Nannapaneni S; Zhou J; Liu W; Marroum P
Clin Ther; 2024 Jan; 46(1):30-39. PubMed ID: 37932155
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics, safety, and immunogenicity of Pelmeg
Wessels H; Lehnick D; Höfler J; Jankowsky R; Chamberlain P; Roth K
Pharmacol Res Perspect; 2019 Oct; 7(5):e00507. PubMed ID: 31417681
[TBL] [Abstract][Full Text] [Related]
24. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers.
Zheng Y; Abuqayyas L; Megally A; Fuhr R; Sałapa K; Downie J; Colice G
Clin Ther; 2021 Jan; 43(1):142-155.e5. PubMed ID: 33380362
[TBL] [Abstract][Full Text] [Related]
25. GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.
von Richter O; Skerjanec A; Afonso M; Sanguino Heinrich S; Poetzl J; Woehling H; Velinova M; Koch A; Kollins D; Macke L; Wuerth G
Br J Clin Pharmacol; 2017 Apr; 83(4):732-741. PubMed ID: 27790726
[TBL] [Abstract][Full Text] [Related]
26. Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects.
Cox DS; Alvarez DF; Bock AE; Cronenberger CL
Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1166-1173. PubMed ID: 33765358
[TBL] [Abstract][Full Text] [Related]
27. Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Sangana R; Xu Y; Shah B; Tian X; Zack J; Shakeri-Nejad K; Kalluri S; Jones I; Ligueros-Saylan M; Taylor AF; Jain DK; Scosyrev E; Uddin A; Laurent N; Paganoni P
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):611-620. PubMed ID: 38389387
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects.
Singh I; Patel A; Patel R; Jose V
Cancer Chemother Pharmacol; 2018 Aug; 82(2):329-337. PubMed ID: 29948023
[TBL] [Abstract][Full Text] [Related]
29. Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.
Metz M; Semsek D; Rogmans G; Hutzschenreuter U; Fietz T; Harde J; Zacharias S; Hielscher C; Lorenz A; Zahn MO; Guth D; Liebers S; Berghorn M; Grebhardt S; Matillon CD; Egerer G; Potthoff K
Support Care Cancer; 2021 Nov; 29(11):6633-6643. PubMed ID: 33956213
[TBL] [Abstract][Full Text] [Related]
30. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
Davidson A; Brimhall D; Kay J; Keystone E; Lee SJ; Kim SH; Bae YJ; Choi EJ; Furst DE
Br J Clin Pharmacol; 2021 Nov; 87(11):4323-4333. PubMed ID: 33822406
[TBL] [Abstract][Full Text] [Related]
31. Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y
Zenklusen I; Hsin CH; Schilling U; Kankam M; Krause A; Ufer M; Dingemanse J
Clin Pharmacokinet; 2022 May; 61(5):687-695. PubMed ID: 34961905
[TBL] [Abstract][Full Text] [Related]
32. Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population.
Wang CY; Park H; Heldermon CD; Vouri SM; Brown JD
J Manag Care Spec Pharm; 2022 Jul; 28(7):795-802. PubMed ID: 35737859
[No Abstract] [Full Text] [Related]
33. A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
Mahtani RL; Belani R; Crawford J; Dale D; DeCosta L; Gawade PL; Huynh C; Lawrence T; Lewis S; MacLaughlin WW; Narang M; Rifkin R
Support Care Cancer; 2022 Jul; 30(7):6135-6144. PubMed ID: 35426046
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim.
Gattu S; Wang J; Bellon A; Schelcher C; Nakov R; Arani R
Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1130-1141. PubMed ID: 34350732
[TBL] [Abstract][Full Text] [Related]
35. A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics.
Bellon A; Wang J; Skerjanec A; Velinova M; Dickerson D; Sabet A; Ngo L; O'Reilly T; Tomek C; Schussler S; Schier-Mumzhiu S; Gattu S; Koch SD; Schelcher C; Dobreva M; Boldea A; Nakov R; Otto GP
Br J Clin Pharmacol; 2020 Jun; 86(6):1139-1149. PubMed ID: 32022282
[TBL] [Abstract][Full Text] [Related]
36. A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adults.
Wynne C; Schwabe C; Stroissnig H; Dias R; Sobierska J; Guenzi E; Otto H; Sattar A; Haliduola HN; Edwald E; Berti F
Expert Opin Biol Ther; 2023; 23(8):773-780. PubMed ID: 36197309
[TBL] [Abstract][Full Text] [Related]
37. Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim.
Desai K; Catalano T; Rai G; Misra P; Shah N
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):354-63. PubMed ID: 27138868
[TBL] [Abstract][Full Text] [Related]
38. PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen
Yao HM; Ottery FD; Borema T; Harris S; Levy J; May TB; Moosavi S; Zhang J; Summers M
BioDrugs; 2019 Apr; 33(2):207-220. PubMed ID: 30900158
[TBL] [Abstract][Full Text] [Related]
39. A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects.
Sabet A; Dickerson DS; Kunina EE; Buccarello AL; Monnet J
Rheumatol Ther; 2022 Apr; 9(2):693-704. PubMed ID: 35262901
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta
Wynne C; Schwabe C; Vincent E; Schueler A; Ryding J; Ullmann M; Ghori V; Kanceva R; Stahl M
Pharmacol Res Perspect; 2020 Apr; 8(2):e00578. PubMed ID: 32333641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
